Technology transfer of Sabin-IPV to new developing country markets
- PMID: 16650773
- DOI: 10.1016/j.biologicals.2006.02.011
Technology transfer of Sabin-IPV to new developing country markets
Abstract
The Netherlands Vaccine Institute (NVI) developed the micro-carrier technology for large-scale production of IPV in the late 1960s and has used this technology successfully to produce IPV as well as DTP-IPV for the national immunization program in the Netherlands. As a public sector organization, and as one of the Millennium Development Goals, NVI has supported over the years access to vaccine technology like DTP and Hib for vaccine manufacturers in developing countries. In line with this role as a resource institute, NVI has recently been approached by a number of vaccine manufacturers, predominantly from developing countries, for transfer of IPV technology to meet the anticipated increase in demand for IPV following OPV cessation. Since WHO encourages new manufacturers to use the attenuated Sabin virus instead of wild polio strains in the production of IPV, NVI decided to respond positively to this WHO policy. The existing NVI experience in large-scale production of IPV and OPV using Vero cell based micro-carrier technology and its experience with experimental Sabin-IPV is an attractive start for the development of Sabin-IPV. This paper discusses the approach followed and the experience already gained in the project, as well as factors critical to its success.
Similar articles
-
Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.Vaccine. 2011 Sep 22;29(41):7188-96. doi: 10.1016/j.vaccine.2011.05.079. Epub 2011 Jun 7. Vaccine. 2011. PMID: 21651934
-
A developing country perspective on vaccine-associated paralytic poliomyelitis.Bull World Health Organ. 2004 Jan;82(1):53-7; discussion 57-8. Epub 2004 Feb 26. Bull World Health Organ. 2004. PMID: 15106301 Free PMC article.
-
Development of inactivated poliovirus vaccine derived from Sabin strains.Biologicals. 2006 Jun;34(2):151-4. doi: 10.1016/j.biologicals.2006.02.010. Epub 2006 May 5. Biologicals. 2006. PMID: 16679028
-
Development of inactivated poliovirus vaccine from Sabin strains: A progress report.Biologicals. 2016 Nov;44(6):581-587. doi: 10.1016/j.biologicals.2016.08.005. Epub 2016 Oct 5. Biologicals. 2016. PMID: 27720268 Review.
-
The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.Vaccine. 2008 Mar 20;26(13):1611-5. doi: 10.1016/j.vaccine.2008.01.034. Epub 2008 Feb 6. Vaccine. 2008. PMID: 18294742 Review.
Cited by
-
Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China.Open Forum Infect Dis. 2019 Aug 26;6(10):ofz380. doi: 10.1093/ofid/ofz380. eCollection 2019 Oct. Open Forum Infect Dis. 2019. PMID: 31660344 Free PMC article.
-
Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.PLoS One. 2013 Dec 12;8(12):e83374. doi: 10.1371/journal.pone.0083374. eCollection 2013. PLoS One. 2013. PMID: 24349497 Free PMC article.
-
History of polio vaccination.World J Virol. 2012 Aug 12;1(4):108-14. doi: 10.5501/wjv.v1.i4.108. World J Virol. 2012. PMID: 24175215 Free PMC article.
-
Vaccinology capacity building in Europe for innovative platforms serving emerging markets.Hum Vaccin Immunother. 2013 Apr;9(4):932-6. doi: 10.4161/hv.23163. Epub 2013 Apr 1. Hum Vaccin Immunother. 2013. PMID: 23563518 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials